Clinical analysis of lacosamide in the treatment of infantile focal epilepsy_Journal of Epilepsy

Authors：

XU Chen ,  TANG Jihong , XIAO Xiao , FENG Jun , ZHANG Bingbing

Department of Neurology, the Children's Hospital Affiliated to Soochow University, Suzhou 215025, China;

Corresponding author：

TANG Jihong, Email: tjhzsh@126.com

Keywords：

Lacosamide; Focal Epilepsy; Infants; Efficacy

DOI：

10.7507/2096-0247.202211004

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To observe the efficacy and safety of lacosamide (LCM) as a monotherapy or as an add-on in the treatment of focal epilepsy in children aged 4 months to 4 years. Methods The study included 20 children with focal epilepsy who received oral LCM monotherapy or add-on therapy in Children's Hospital Affiliated to Soochow University from March 2022 to September 2022, including 9 males and 11 females with an average age of (22.4±13.0) months. The curative effects and adverse reactions at 1, 2, 3, 4, and 6 months after LCM treatment were analyzed. The initial dose of LCM was 2 mg/(kg·d) and increased by 2 mg/(kg·d) every week, maintenance dose 6 ~ 12mg/(kg·d). Results During the follow-up period of this study, the total effective cases were 17 (85.00%), and the number of control-free cases was 15 (75.00%). Conclusion LCM can effectively reduce the frequency of epileptic seizures in the monotherapy or add-on treatment of infants and young children with focal epilepsy, with few adverse reactions and high retention rate, which has high clinical application value.

Citation： XU Chen, TANG Jihong, XIAO Xiao, FENG Jun, ZHANG Bingbing. Clinical analysis of lacosamide in the treatment of infantile focal epilepsy. Journal of Epilepsy, 2023, 9(1): 22-25. doi: 10.7507/2096-0247.202211004 Copy

1.	Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology, 2017, 88(3): 296-303.
2.	European Medicines Agency. Lacosamide: summary of product characteristics [EB/OL]. [2020-12-01].
3.	US FDA. Vimpat@（lacosamide）: highlights of prescribing information [EB/OL]. [2020-11-01].
4.	French JA, Cleary E, Dlugos D, et al. Considerations for determining the efficacy of new antiseizure medications in children age 1 month to younger than 2 years. Epilepsia, 2022, 63(10): 2664-2670.
5.	Harris JA, Murphy JA. Lacosamide and epilepsy. CNS Neurosci Ther, 2011, 17(6): 678-682.
6.	Patyar S, Medhi B. Lacosamide, a newer antiepileptic. Neurosciences, 2010, 15(1): 3-6.
7.	Brustovetsky T, Khanna R, Brustovetsky N. CRMP2 is involved in regulation of mitochondrial morphology and motility in neurons. Cells, 2021, 10(10): 2781.
8.	Toupin JF, Lortie A, Major P, et al. Efficacy and safety of lacosamide as an adjunctive therapy for refractory focal epilepsy in paediatric patients: a retrospective single-centre study. Epileptic Disord, 2015, 17(4): 436-443.
9.	May TW, Brandt C, Helmer R, et al. Comparison of lacosamide concentrations in cerebrospinal fluid and serum in patients with epilepsy. Epilepsia, 2015, 56(7): 1134-1140.
10.	Ishikawa N, Eguchi Y, Izumo H, et al. Clinical impact of the dose and blood concentration of lacosamide in Japanese pediatric patients with epilepsy: A cohort study. Epilepsy Behav, 2022, 129: 108614.
11.	Akbar A, Harthan AA, Creeden S, et al. Response of focal refractory status epilepticus to lacosamide in an infant. BMJ Case Rep, 2022, 15(4): e249948.
12.	冯隽, 汤继宏, 张兵兵, 等. 拉考沙胺单药治疗儿童良性癫痫伴中央颞区棘波的临床分析. 癫痫杂志, 2021, 7(6): 477-480.
13.	Okanishi T, Fujii Y, Sakuma S, et al. Lacosamide monotherapy for the treatment of childhood epilepsy with centrotemporal spikes. Brain Dev, 2022, 44(6): 380-385.
14.	Flor-Hirsch H, Heyman E, Livneh A, et al. Lacosamide for SCN2A-related intractable neonatal and infantile seizures. Epileptic Disord, 2018, 20(5): 440-446.
15.	廖红梅, 康庆云, 吴丽文, 等. 拉考沙胺在低龄婴儿钠离子通道相关癫痫中的应用. 中华神经科杂志, 2022, 55(8): 826-833.
16.	Li J, Sun M, Wang X. The adverse-effect profile of lacosamide. Expert Opin Drug Saf, 2020, 19(2): 131-138.
17.	Brodie MJ. Practical use of newer antiepileptic drugs as adjunctive therapy in focal epilepsy. CNS Drugs, 2015, 29(11): 893-904.
18.	Stephen LJ, Kelly K, Parker P, et al. Adjunctive lacosamide: 5 years clinical experience. Epilepsy Res, 2014, 108: 1385-1391.
19.	Shepard PW, St Louis EK. Seizure treatment in transplant patients. Curr Treat Options Neurol, 2012, 14(4): 332-347.
20.	Yang C, Yang Y, Peng Y, et al. Efficacy and safety of lacosamide in pediatric patients with epilepsy: a systematic review and meta-analysis. Epilepsy Behav, 2022, 134: 108781.

1. Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology, 2017, 88(3): 296-303.
2. European Medicines Agency. Lacosamide: summary of product characteristics [EB/OL]. [2020-12-01].
3. US FDA. Vimpat@（lacosamide）: highlights of prescribing information [EB/OL]. [2020-11-01].
4. French JA, Cleary E, Dlugos D, et al. Considerations for determining the efficacy of new antiseizure medications in children age 1 month to younger than 2 years. Epilepsia, 2022, 63(10): 2664-2670.
5. Harris JA, Murphy JA. Lacosamide and epilepsy. CNS Neurosci Ther, 2011, 17(6): 678-682.
6. Patyar S, Medhi B. Lacosamide, a newer antiepileptic. Neurosciences, 2010, 15(1): 3-6.
7. Brustovetsky T, Khanna R, Brustovetsky N. CRMP2 is involved in regulation of mitochondrial morphology and motility in neurons. Cells, 2021, 10(10): 2781.
8. Toupin JF, Lortie A, Major P, et al. Efficacy and safety of lacosamide as an adjunctive therapy for refractory focal epilepsy in paediatric patients: a retrospective single-centre study. Epileptic Disord, 2015, 17(4): 436-443.
9. May TW, Brandt C, Helmer R, et al. Comparison of lacosamide concentrations in cerebrospinal fluid and serum in patients with epilepsy. Epilepsia, 2015, 56(7): 1134-1140.
10. Ishikawa N, Eguchi Y, Izumo H, et al. Clinical impact of the dose and blood concentration of lacosamide in Japanese pediatric patients with epilepsy: A cohort study. Epilepsy Behav, 2022, 129: 108614.
11. Akbar A, Harthan AA, Creeden S, et al. Response of focal refractory status epilepticus to lacosamide in an infant. BMJ Case Rep, 2022, 15(4): e249948.
12. 冯隽, 汤继宏, 张兵兵, 等. 拉考沙胺单药治疗儿童良性癫痫伴中央颞区棘波的临床分析. 癫痫杂志, 2021, 7(6): 477-480.
13. Okanishi T, Fujii Y, Sakuma S, et al. Lacosamide monotherapy for the treatment of childhood epilepsy with centrotemporal spikes. Brain Dev, 2022, 44(6): 380-385.
14. Flor-Hirsch H, Heyman E, Livneh A, et al. Lacosamide for SCN2A-related intractable neonatal and infantile seizures. Epileptic Disord, 2018, 20(5): 440-446.
15. 廖红梅, 康庆云, 吴丽文, 等. 拉考沙胺在低龄婴儿钠离子通道相关癫痫中的应用. 中华神经科杂志, 2022, 55(8): 826-833.
16. Li J, Sun M, Wang X. The adverse-effect profile of lacosamide. Expert Opin Drug Saf, 2020, 19(2): 131-138.
17. Brodie MJ. Practical use of newer antiepileptic drugs as adjunctive therapy in focal epilepsy. CNS Drugs, 2015, 29(11): 893-904.
18. Stephen LJ, Kelly K, Parker P, et al. Adjunctive lacosamide: 5 years clinical experience. Epilepsy Res, 2014, 108: 1385-1391.
19. Shepard PW, St Louis EK. Seizure treatment in transplant patients. Curr Treat Options Neurol, 2012, 14(4): 332-347.
20. Yang C, Yang Y, Peng Y, et al. Efficacy and safety of lacosamide in pediatric patients with epilepsy: a systematic review and meta-analysis. Epilepsy Behav, 2022, 134: 108781.

Journal of Epilepsy

Clinical analysis of lacosamide in the treatment of infantile focal epilepsy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content